Rohan T E, Hartwick W, Miller A B, Kandel R A
Department of Public Health Sciences, University of Toronto, ON, Canada.
J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9. doi: 10.1093/jnci/90.17.1262.
We studied the associations between c-erbB-2 protein overexpression and p53 protein accumulation in benign breast tissue and the risk of subsequent breast cancer.
We conducted a case-control study nested within the cohort of 4888 women in the National Breast Screening Study (NBSS) who were diagnosed with benign breast disease during active follow-up. Case subjects were the women who subsequently developed breast cancer (ductal carcinoma in situ [DCIS] or invasive carcinoma). Control subjects were matched to each case subject on NBSS study arm, screening center, year of birth, and age at diagnosis of benign breast disease. Histologic sections of benign and cancerous breast tissues were analyzed immunohistochemically. Information on potential confounding factors was obtained by use of a self-administered lifestyle questionnaire.
Accumulation of p53 protein was associated with an increased risk of progression to breast cancer (adjusted odds ratio [OR] = 2.55; 95% confidence interval [CI] = 1.01-6.40), whereas c-erbB-2 protein overexpression was not (adjusted OR = 0.65; 95% CI = 0.27-1.53). The findings for c-erbB-2 and p53 did not differ among strata defined by menopausal status, allocation within the NBSS, history of breast disease, and whether the benign breast disease was detected at a scheduled screen or between screens. The results were also similar after exclusion of case subjects whose diagnosis of breast cancer occurred within 1 year of their diagnosis of benign breast disease and after exclusion of subjects with DCIS.
p53 protein accumulation, but not c-erbB-2 protein overexpression, appears to be associated with an increased risk of progression to breast cancer in women with benign breast disease.
我们研究了良性乳腺组织中c-erbB-2蛋白过度表达和p53蛋白积聚之间的关联以及后续患乳腺癌的风险。
我们在国家乳腺筛查研究(NBSS)的4888名女性队列中进行了一项巢式病例对照研究,这些女性在积极随访期间被诊断为良性乳腺疾病。病例组为随后发生乳腺癌(导管原位癌[DCIS]或浸润性癌)的女性。对照组在NBSS研究组、筛查中心、出生年份和良性乳腺疾病诊断时的年龄方面与每个病例组进行匹配。对良性和癌性乳腺组织的组织学切片进行免疫组织化学分析。通过自行填写的生活方式问卷获取潜在混杂因素的信息。
p53蛋白积聚与进展为乳腺癌的风险增加相关(调整后的比值比[OR]=2.55;95%置信区间[CI]=1.01-6.40),而c-erbB-2蛋白过度表达则不然(调整后的OR=0.65;95%CI=0.27-1.53)。在按绝经状态、NBSS内的分组、乳腺疾病史以及良性乳腺疾病是在预定筛查时还是在筛查之间检测到所定义的各层中,c-erbB-2和p53的研究结果没有差异。在排除乳腺癌诊断在良性乳腺疾病诊断后1年内的病例组以及排除DCIS患者后,结果也相似。
p53蛋白积聚而非c-erbB-2蛋白过度表达似乎与良性乳腺疾病女性进展为乳腺癌的风险增加相关。